Skip to main content

BOSTON SCIENTIFIC CORP

corporate_fare Company Profile

BOSTON SCIENTIFIC CORP

BSX·NYSE·Life Sciences·CIK 0000885725

Boston Scientific Corporation develops, manufactures, and markets medical devices globally for various interventional medical specialties. The company has been a medical technology leader for over 45 years, focusing on less-invasive medicine by providing alternatives to surgery and other traumatic medical procedures. Their solutions help medical professionals diagnose and treat a wide range of diseases and conditions, aiming to improve patient health and reduce healthcare costs. The company operates under five strategic imperatives: Strengthen Category Leadership, Expand into High Growth Adjacencies, Drive Global Expansion, Fund the Journey to Fuel Growth, and Develop Key Capabilities. Boston Scientific invests in its core businesses and seeks opportunities to diversify and expand into strategic, high-growth areas and new global markets, including emerging markets. Maintaining and expanding its international presence is a key part of its long-term growth strategy, aiming to increase net sales and market share, leverage physician relationships, accelerate new product launches, and access worldwide technological developments. Research and development efforts are concentrated on next-generation and novel technology offerings across multiple programs and all divisions.

BOSTON SCIENTIFIC CORP (NYSE:BSX) is a publicly traded company in the Life Sciences sector. Wiseek monitors BSX SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Boston Scientific to Acquire Penumbra in Multi-Billion Dollar Cash and Stock Deal
  • Boston Scientific to Acquire Penumbra for $14.5 Billion, Expanding Cardiovascular and Neurovascular Portfolio

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$20.07B
Net Income
$2.89B
Diluted EPS
$1.94
Op. Cash Flow
$4.53B
Free Cash Flow
$3.66B
Gross Profit
$13.85B
Operating Income
$3.61B
Cash & Equivalents
$1.97B
Total Debt
$299M
Debt / Equity
0.01×
Net Margin
14.4%
Shares Outstanding
1.48B sh
Source: 10-K · filed 2026-02-17 · accession 0000885725-26-000010

Recent Capital Actions

  • 2026-02-27 Proposed Mixed Merger +43.85M sh

    ing: 1 Feb. 26, 2026 USD ($) shares a: Offering: a: Fee Previously Paid false a: Rule 457(a) true a: Security Type Equity a: Security Class Title Common Stock, $0.01 par value per share a: Amount Registered | shares…

  • 2026-02-26 Executed Long-term debt ↓ −$3.27B (net of 7 line items)

    ereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to…

  • 2026-02-26 Executed Total debt ↓ −$3.27B (net of 7 line items)

    ereto, and Wells Fargo Bank, National Association, as administrative agent. Under the Term Loan Credit Agreement, the Company may borrow (i) a 364-day delayed draw term loan in an aggregate principal amount of up to…

Detected from SEC filings (8-K, S-4, POS AM, 6-K). Last 12 months.
$46.91
52-week range · as of 2026-05-18 $52.52 – $109.5
Market cap
$69.72B
Volume
16.8M (0.8× avg)
3-mo avg 21.2M
Live data · 2026-06-14 06:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BSX - Filings & News (Page 2)

BSX
Jan 15, 2026, 5:05 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $89.46
Real-time Price: $46.91 info
Change: -$42.55 (-48%) info
Market Cap: $69.725B info
BSX
Jan 15, 2026, 7:21 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $89.00
Real-time Price: $46.91 info
Change: -$42.09 (-47%) info
Market Cap: $69.725B info